APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Immuno Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oncology Immuno Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026187 pages

Choose your research edition.

Industry ResearchOncology Immuno Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Immuno Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Oncology Immuno Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Immuno Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Immuno Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Oncology Immuno Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oncology Immuno Drug include Bristol-Myers Squibb, Dendreon Pharmaceuticals, Gilead Sciences Inc., Merck & Co, Sanofi S.A., AstraZeneca, Roche AG, Merck KGaA and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oncology Immuno Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Immuno Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Immuno Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncology Immuno Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology Immuno Drug Segment by Company

Bristol-Myers Squibb

Dendreon Pharmaceuticals

Gilead Sciences Inc.

Merck & Co

Sanofi S.A.

AstraZeneca

Roche AG

Merck KGaA

Novartis

Oncology Immuno Drug Segment by Type

CAR-T Cell Therapy

Cancer Vaccines

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Oncology Immuno Drug Segment by Application

Hospitals

Drugstores

Others

Oncology Immuno Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Immuno Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Immuno Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Immuno Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oncology Immuno Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oncology Immuno Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oncology Immuno Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oncology Immuno Drug Industry Trends Table 2. Oncology Immuno Drug Industry Drivers Table 3. Oncology Immuno Drug Industry Opportunities and Challenges Table 4. Oncology Immuno Drug Industry Restraints Table 5. Global Oncology Immuno Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oncology Immuno Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Oncology Immuno Drug Sales Market Share by Manufacturers Table 9. Global Oncology Immuno Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oncology Immuno Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oncology Immuno Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oncology Immuno Drug Manufacturers, Product Type & Application Table 13. Global Oncology Immuno Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oncology Immuno Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CAR-T Cell Therapy Table 17. Major Manufacturers of Cancer Vaccines Table 18. Major Manufacturers of Cytokine-Based Immunotherapy Table 19. Major Manufacturers of Immune Checkpoint Inhibitors Table 20. Major Manufacturers of Other Table 21. Global Oncology Immuno Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Oncology Immuno Drug Sales Market Share by Type (2021-2026) Table 25. Global Oncology Immuno Drug Sales Market Share by Type (2027-2032) Table 26. Global Oncology Immuno Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Oncology Immuno Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Oncology Immuno Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Oncology Immuno Drug Revenue Market Share by Type (2021-2026) Table 30. Global Oncology Immuno Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Drugstores Table 33. Major Manufacturers of Others Table 34. Global Oncology Immuno Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Oncology Immuno Drug Sales Market Share by Application (2021-2026) Table 38. Global Oncology Immuno Drug Sales Market Share by Application (2027-2032) Table 39. Global Oncology Immuno Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Oncology Immuno Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Oncology Immuno Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Oncology Immuno Drug Revenue Market Share by Application (2021-2026) Table 43. Global Oncology Immuno Drug Revenue Market Share by Application (2027-2032) Table 44. Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Oncology Immuno Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Oncology Immuno Drug Sales Market Share by Region (2021-2026) Table 47. Global Oncology Immuno Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Oncology Immuno Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Oncology Immuno Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Oncology Immuno Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Oncology Immuno Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Oncology Immuno Drug Revenue Market Share by Region (2021-2026) Table 65. Global Oncology Immuno Drug Revenue Market Share by Region (2027-2032) Table 66. Bristol-Myers Squibb Company Information Table 67. Bristol-Myers Squibb Business Overview Table 68. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio Table 70. Bristol-Myers Squibb Recent Development Table 71. Dendreon Pharmaceuticals Company Information Table 72. Dendreon Pharmaceuticals Business Overview Table 73. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio Table 75. Dendreon Pharmaceuticals Recent Development Table 76. Gilead Sciences Inc. Company Information Table 77. Gilead Sciences Inc. Business Overview Table 78. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio Table 80. Gilead Sciences Inc. Recent Development Table 81. Merck & Co Company Information Table 82. Merck & Co Business Overview Table 83. Merck & Co Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Merck & Co Oncology Immuno Drug Product Portfolio Table 85. Merck & Co Recent Development Table 86. Sanofi S.A. Company Information Table 87. Sanofi S.A. Business Overview Table 88. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Sanofi S.A. Oncology Immuno Drug Product Portfolio Table 90. Sanofi S.A. Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. AstraZeneca Oncology Immuno Drug Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Roche AG Company Information Table 97. Roche AG Business Overview Table 98. Roche AG Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Roche AG Oncology Immuno Drug Product Portfolio Table 100. Roche AG Recent Development Table 101. Merck KGaA Company Information Table 102. Merck KGaA Business Overview Table 103. Merck KGaA Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Merck KGaA Oncology Immuno Drug Product Portfolio Table 105. Merck KGaA Recent Development Table 106. Novartis Company Information Table 107. Novartis Business Overview Table 108. Novartis Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Novartis Oncology Immuno Drug Product Portfolio Table 110. Novartis Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Oncology Immuno Drug Distributors List Table 114. Oncology Immuno Drug Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Oncology Immuno Drug Product Image Figure 2. Global Oncology Immuno Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Immuno Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncology Immuno Drug Sales (2021-2032) & (K Units) Figure 5. Global Oncology Immuno Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oncology Immuno Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CAR-T Cell Therapy Image Figure 9. Cancer Vaccines Image Figure 10. Cytokine-Based Immunotherapy Image Figure 11. Immune Checkpoint Inhibitors Image Figure 12. Other Image Figure 13. Global Oncology Immuno Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Oncology Immuno Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Oncology Immuno Drug Sales Market Share by Type (2021-2032) Figure 16. Global Oncology Immuno Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Oncology Immuno Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Oncology Immuno Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Drugstores Image Figure 21. Others Image Figure 22. Global Oncology Immuno Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Oncology Immuno Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Oncology Immuno Drug Sales Market Share by Application (2021-2032) Figure 25. Global Oncology Immuno Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Oncology Immuno Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Oncology Immuno Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Oncology Immuno Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Oncology Immuno Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Oncology Immuno Drug Sales Market Share by Country (2021-2032) Figure 42. China Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Oncology Immuno Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Oncology Immuno Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Oncology Immuno Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Oncology Immuno Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Oncology Immuno Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Oncology Immuno Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Dendreon Pharmaceuticals
  • Gilead Sciences Inc.
  • Merck & Co
  • Sanofi S.A.
  • AstraZeneca
  • Roche AG
  • Merck KGaA
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncology Immuno Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncology Immuno Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oncology Immuno Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oncology Immuno Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oncology Immuno Drug Market Dynamics
  1. 2.1 Oncology Immuno Drug Industry Trends
  2. 2.2 Oncology Immuno Drug Industry Drivers
  3. 2.3 Oncology Immuno Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Immuno Drug Industry Restraints
3 Oncology Immuno Drug Market by Manufacturers
  1. 3.1 Global Oncology Immuno Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oncology Immuno Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oncology Immuno Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oncology Immuno Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oncology Immuno Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oncology Immuno Drug Manufacturers, Product Type & Application
  7. 3.7 Global Oncology Immuno Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oncology Immuno Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oncology Immuno Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oncology Immuno Drug Tier 1, Tier 2, and Tier 3
4 Oncology Immuno Drug Market by Type
  1. 4.1 Oncology Immuno Drug Type Introduction
  2. 4.1.1 CAR-T Cell Therapy
  3. 4.1.2 Cancer Vaccines
  4. 4.1.3 Cytokine-Based Immunotherapy
  5. 4.1.4 Immune Checkpoint Inhibitors
  6. 4.1.5 Other
  7. 4.2 Global Oncology Immuno Drug Sales by Type
  8. 4.2.1 Global Oncology Immuno Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oncology Immuno Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Oncology Immuno Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Oncology Immuno Drug Revenue by Type
  12. 4.3.1 Global Oncology Immuno Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Oncology Immuno Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Oncology Immuno Drug Revenue Market Share by Type (2021-2032)
5 Oncology Immuno Drug Market by Application
  1. 5.1 Oncology Immuno Drug Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Oncology Immuno Drug Sales by Application
  6. 5.2.1 Global Oncology Immuno Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oncology Immuno Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Oncology Immuno Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Oncology Immuno Drug Revenue by Application
  10. 5.3.1 Global Oncology Immuno Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oncology Immuno Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Oncology Immuno Drug Revenue Market Share by Application (2021-2032)
6 Global Oncology Immuno Drug Sales by Region
  1. 6.1 Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Immuno Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Oncology Immuno Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Oncology Immuno Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oncology Immuno Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oncology Immuno Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oncology Immuno Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oncology Immuno Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oncology Immuno Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oncology Immuno Drug Revenue by Region
  1. 7.1 Global Oncology Immuno Drug Revenue by Region
  2. 7.1.1 Global Oncology Immuno Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oncology Immuno Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Oncology Immuno Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Oncology Immuno Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oncology Immuno Drug Revenue (2021-2032)
  8. 7.2.2 North America Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oncology Immuno Drug Revenue (2021-2032)
  11. 7.3.2 Europe Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oncology Immuno Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oncology Immuno Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oncology Immuno Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Dendreon Pharmaceuticals
  8. 8.2.1 Dendreon Pharmaceuticals Company Information
  9. 8.2.2 Dendreon Pharmaceuticals Business Overview
  10. 8.2.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
  12. 8.2.5 Dendreon Pharmaceuticals Recent Developments
  13. 8.3 Gilead Sciences Inc.
  14. 8.3.1 Gilead Sciences Inc. Company Information
  15. 8.3.2 Gilead Sciences Inc. Business Overview
  16. 8.3.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
  18. 8.3.5 Gilead Sciences Inc. Recent Developments
  19. 8.4 Merck & Co
  20. 8.4.1 Merck & Co Company Information
  21. 8.4.2 Merck & Co Business Overview
  22. 8.4.3 Merck & Co Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co Oncology Immuno Drug Product Portfolio
  24. 8.4.5 Merck & Co Recent Developments
  25. 8.5 Sanofi S.A.
  26. 8.5.1 Sanofi S.A. Company Information
  27. 8.5.2 Sanofi S.A. Business Overview
  28. 8.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
  30. 8.5.5 Sanofi S.A. Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Oncology Immuno Drug Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Roche AG
  38. 8.7.1 Roche AG Company Information
  39. 8.7.2 Roche AG Business Overview
  40. 8.7.3 Roche AG Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche AG Oncology Immuno Drug Product Portfolio
  42. 8.7.5 Roche AG Recent Developments
  43. 8.8 Merck KGaA
  44. 8.8.1 Merck KGaA Company Information
  45. 8.8.2 Merck KGaA Business Overview
  46. 8.8.3 Merck KGaA Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck KGaA Oncology Immuno Drug Product Portfolio
  48. 8.8.5 Merck KGaA Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Oncology Immuno Drug Product Portfolio
  54. 8.9.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oncology Immuno Drug Value Chain Analysis
  2. 9.1.1 Oncology Immuno Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oncology Immuno Drug Production Mode & Process
  6. 9.2 Oncology Immuno Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oncology Immuno Drug Distributors
  9. 9.2.3 Oncology Immuno Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst